Skip to content
TirzepatideReport

Tirzepatide monograph · Evidence review

The Edit Tirzepatide Review: $309/Month, the $209 Promo & Verdict (2026)

The Edit charges $309/month for compounded tirzepatide month-to-month. The $209 it advertises is a first-order coupon, not the standing rate.

Researched & written by Alan Pierce · last updated

Clinical Pharmacology Writer

On this page

Editorial pick

CoreAge Rx

$149/mo flat

Doctor-reviewed tirzepatide with one flat price and built-in human support.

Advertising disclosure · we may earn a commission at no extra cost to you.

Check availability
vs median
$128/mo below the $277 median
Market
$109–$429/mo across 363 providers
Dispensed
Compounded tirzepatide (503A)

Popular alternative

Found

Established, physician-designed weight care with a broad formulary — real brand-name Zepbound/Mounjaro alongside compounded tirzepatide, paired with coaching.

$289/mo m2m ($169/mo on 12-mo prepay)

Check Found availability

Compounded tirzepatide at The Edit is $309 a month if you pay month to month. The number the site puts in front of you first is $209, and that is a $100-off first-order coupon — one month, then $309 for every month after it. We read the company's own product catalog and its six product pages in August 2026. This page carries no outbound link; every figure below comes from the company's own published pages.

The tirzepatide ladder

There are three ways to buy it, and all three are published in the same place:

How you payWhat you hand overWorks out at
Month to month$309 each month$309/month — the standing rate
3 months up front$855 billed once$285/month
6 months up front$1,575 billed once$263/month
First order only$209a $100 coupon, once

§ The Edit — the tirzepatide rungs, read August 2026

How you payWhat you hand overWorks out at
Month to month$309 each month$309/month — the standing rate
3 months up front$855 billed once$285/month
6 months up front$1,575 billed once$263/month
First order only$209a $100 coupon, once — not a rate
Every division checks out: $855 ÷ 3 = $285 exactly, $1,575 ÷ 6 = $262.50. The prepay rungs are labeled "billed once", so the commitment is visible. The $209 is a $100-off coupon on the first order only.

Now the part that is genuinely unusual: the arithmetic is honest. $855 divided by three is exactly $285. $1,575 divided by six is $262.50, which is where the advertised $263 comes from. Both prepay rungs are labeled "billed once at the start of the plan," so the commitment is stated rather than hidden inside a per-month figure. On this site we spend most of our time unpicking providers whose "/month" number is an annual prepay divided by twelve. The Edit is not doing that.

What it is doing is leading with the coupon. $209 is a real price you can pay — once. If you are comparing providers on a spreadsheet, the cell that belongs in it is $309, and the cell that belongs beside it is $285 or $263 with the words "pay $855" or "pay $1,575 today" attached.

Who actually writes the prescription

The Edit Health LLC is a Texas MSO in Austin — the business layer. The clinical layer is Arora Health & Aesthetics, LLC, medical director Dr. Sean Arora, NPI 1841729449. We checked that number against the national provider registry: active, Seattle WA, family medicine, licensed in New Hampshire, Michigan and Washington.3 Naming a medical director and publishing an NPI that resolves is more than most of this category manages.

One thing to know before you treat this as a second opinion. Trellis Vitality, which sells tirzepatide at $199 a month, runs on the same medical group and the same medical director. Different pharmacies, different prices, genuinely separable products — but if you shortlist both and think you are choosing between two independent clinical organizations, you are not. You are choosing between two price sheets attached to one prescriber network.

The pharmacy is named, which is rarer than it should be

The Edit names The Pharmacy Hub as the compounder inside what it calls its pharmacy network. That is a checkable fact rather than the "an FDA-registered U.S. pharmacy" boilerplate that tells a reader nothing. Two of the providers we looked at in the same batch — Rehydra+ Wellness and Auren Rx — never name a pharmacy at all.

Fees, refunds and getting out

Nothing is charged to start. The site's language is explicit: there is no charge and no card on file to begin, and if a clinician does not approve you, you are refunded in full. A visit fee becomes non-refundable once a visit has actually happened, which is a different and much fairer thing than a fee levied before anyone has looked at you.

Once the medication ships it is final sale, as compounded prescriptions generally are. Membership cancels at the end of the current period with no proration, under a cancellation policy the company dates to July 2026. The prepay plans are the place to be careful: a six-month plan is $1,575 you have already spent, and "cancel anytime" is about the subscription, not about that money.

The rest of the shelf

Six protocols, five injectable and one cream: compounded semaglutide at $209/month, compounded tirzepatide at $309, NAD+ at $249, glutathione at $199, sermorelin at $169, and GHK-Cu cream at $129.1 The product list and the individual product pages agree with each other exactly, which sounds like a low bar until you have read enough of these sites to know how often two surfaces on the same domain publish two different prices.

There is no oral GLP-1, no nasal line, no retatrutide, and the site states plainly that it does not sell research-use-only compounds. Compare that with Pepti, whose sixty-eight-item catalog includes retatrutide, melanotan II and IGF-1 LR3 alongside the tirzepatide.

The Spanish site

The Edit ships a complete `/es/` mirror — every page, thirty-three Spanish URLs in its own sitemap. No other row here does this. If English is not the language you want to read a consent form and a titration schedule in, that is a material difference and not a marketing flourish.

The regulatory screen

We ran the trading name, the legal entity, the medical group and the named pharmacy against the FDA's live warning-letter index in August 2026. Every query returned zero matches in the company column.2 That screen carried a positive control — an unrelated telehealth seller with a real letter dated February 2026 — and the control returned correctly on every pass,4 so the zeroes here are evidence rather than a query that quietly failed. The Edit does not appear on either of the 2025 or 2026 compounded-GLP-1 sweeps.

Brand versus compounded

This is compounded tirzepatide, not Zepbound. Compounded tirzepatide is pharmacy-made, is not itself an FDA-approved finished drug, and was not the product studied in the pivotal trials. Our guide to whether compounded tirzepatide is still legal in 2026 sets out where that stands after the shortage ended.

Does the molecule work? (Separate question)

Keep the provider and the drug apart in your head. In the 72-week SURMOUNT-1 trial, adults without diabetes lost roughly 15% to 21% of body weight across the 5–15 mg doses, against about 3% on placebo5. Against semaglutide in SURMOUNT-5, tirzepatide produced about 20% versus 14%6. Both results came from the brand molecule at approved doses. The full picture is in our tirzepatide evidence guide.

The honest verdict

$309 a month is not cheap for compounded tirzepatide — it sits in the upper half of the field, and there are providers in our ranking charging a hundred dollars less for the same molecule. What The Edit buys you at that price is a set of things this category usually withholds: a named compounder, a named medical director with an NPI that resolves, a price ladder whose divisions are correct and whose commitments are labeled, no charge before a clinician has looked at you, and a full Spanish site. The one thing to hold onto is that $209 is a coupon and $309 is the price, and the second thing is that Trellis is not a second opinion on The Edit. Read the ladder against the rest of the field in our tirzepatide price index, or start from the ranked best tirzepatide providers ranking.

Frequently asked questions

How much does tirzepatide cost at The Edit?

$309 a month if you pay month to month. Paying three months up front is $855 billed once, which works out at $285 a month; six months up front is $1,575 billed once, or $263 a month. The $209 figure the site leads with is a $100-off coupon that applies to your first order only.

Is the $209 tirzepatide price real?

Yes, for one month. It is a $100 discount off the standing $309 rate on your first order. Month two onward is $309 unless you have prepaid a three- or six-month plan.

Does The Edit name its pharmacy?

Yes — The Pharmacy Hub, within what it calls The Edit Health Pharmacy Network. It also names its medical group, Arora Health & Aesthetics, and its medical director, Dr. Sean Arora, whose NPI 1841729449 resolves to an active family-medicine registration in Seattle.

Is The Edit the same company as Trellis Vitality?

No, but they share a clinical layer. Both run on Arora Health & Aesthetics under the same medical director. Their pharmacies and prices differ, so they are separable products — but they are not two independent clinical opinions, and shortlisting both does not give you the second look you might think it does.

What does The Edit charge for semaglutide?

$209 a month month-to-month, with $575 for three months ($192/month) and $1,065 for six ($178/month), plus the same $100 first-order coupon. Its other products are NAD+ at $249, glutathione at $199, sermorelin at $169 and GHK-Cu cream at $129.

References(6)

  1. The Edit Health LLC (2026). Products and program pricing — compounded tirzepatide, semaglutide, NAD+, glutathione, sermorelin and GHK-Cu. theedithealth.com. https://theedithealth.com/
  2. U.S. Food and Drug Administration (2026). Warning Letters (searchable index). FDA.gov. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
  3. Centers for Medicare & Medicaid Services (2026). NPPES NPI Registry — national provider identifier lookup. npiregistry.cms.hhs.gov. https://npiregistry.cms.hhs.gov/
  4. U.S. Food and Drug Administration (2026). Warning Letter — Lean Rx, Inc. dba SkinnyRx (the positive control used to validate the warning-letter screen). FDA.gov. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/lean-rx-inc-dba-skinnyrx-717989-02202026
  5. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, and the SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
  6. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Bays HE, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).. New England Journal of Medicine. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/

About the author

Alan Pierce

Clinical Pharmacology Writer

About Tirzepatide Report · How we verify prices · This page last updated August 2026

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.